Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) a review of evidence and clinical interpretation.

CONCLUSIONS: Compared with earlier insulin analogues, second-generation basal insulins have improved pharmacokinetic/pharmacodynamic profiles that translate into clinical benefits, primarily reduced nocturnal-hypoglycaemia risk. Additional head-to-head comparisons of insulin degludec and insulin glargine 300 U/mL at bioequivalent doses, utilising continuous glucose monitoring and/or real-world evidence, are required to elucidate the differences in their pharmacological and clinical profiles. PMID: 30496834 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30496834?dopt=Abstract

Source: Diabetes and Metabolism - November 26, 2018 Category: Endocrinology Authors: R Owens D, S Bailey T, Fanelli C, Yale JF, Bolli GB Tags: Diabetes Metab Source Type: research